ArticleSubstance abuse and rehabilitation2026
Nighttime Sleep Symptoms and Sleep-Relevant Medication Documentation Among Adults Receiving Buprenorphine for Opioid Use Disorder.
Article in Substance abuse and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sleep-related symptoms are common among people receiving medications for opioid use disorder (OUD), including buprenorphine. In outpatient addiction treatment, nighttime sleep complaints are often evaluated alongside active medication lists and recent substance exposures. This short report described patient-reported nighttime sleep symptoms and sleep-relevant medication class documentation among adults receiving buprenorphine for OUD. Methods: This cross-sectional study used survey data and medical-record abstraction from adults receiving buprenorphine for OUD at an academic addiction clinic from February 2022 to September 2023. Nighttime sleep symptoms were characterized using Insomnia Severity Index items 1-3: difficulty falling asleep, difficulty staying asleep, and waking too early. Participants were categorized as No-Sx, Single-Sx, or Multi-Sx. Sleep-relevant medications documented on the active outpatient medication list were grouped into eight classes. Sample characteristics, nighttime symptom groups, medication class documentation, and urine drug testing results within 30 days were summarized descriptively. Results: Among study participants (n = 136), 72.1% endorsed at least one nighttime sleep symptom. Symptom group distribution was No-Sx (27.9%), Single-Sx (11.0%), and Multi-Sx (61.0%). In the Multi-Sx group, gabapentinoids were most frequently documented (34.9%), followed by sedating antidepressants (26.5%), sedating antihistamines (22.9%), and adrenergic agents (22.9%). Cannabinoids were detected in 46.2% of participants with available urine drug testing results. Conclusion: Nighttime sleep symptoms and sleep-relevant medication documentation were common in this outpatient buprenorphine-treated OUD sample. Findings support routine nighttime sleep symptom assessment, together with medication review and consideration of recent substance exposure, to help identify clinically relevant sleep concerns and inform safer outpatient buprenorphine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.